Search results
27 maj 2014 · Available fetal therapies, including medical management for arrhythmias or heart failure and closed or open intervention for diseases affecting the cardiovascular system such as twin-twin transfusion syndrome, lung masses, and vascular tumors, are highlighted.
- Congenital heart disease: types, pathophysiology, diagnosis, and ...
Pathological type and treatment options of atrial septal...
- Prenatal Diagnosis of Fetal Heart Failure - PMC - National Center for ...
Diagnosis of FHF is based on various fetal echocardiographic...
- Congenital heart disease: types, pathophysiology, diagnosis, and ...
Available fetal therapies, including medical management for arrhythmias or heart failure and closed or open intervention for diseases affecting the cardiovascular system such as twin–twin transfusion syndrome, lung masses, and vascular tumors, are highlighted.
24 kwi 2014 · This article covers important topics relevant to fetal cardiac medicine, including the diagnosis of heart disease, assessment of cardiac function and the cardiovascular system, and treatment options that are available.
29 cze 2024 · New techniques, modalities, and therapies are emerging to aid in prenatal diagnosis, prognostication, and management of congenital heart disease and arrhythmias. Prenatal diagnosis of heart disease and our options for in utero management are improving.
5 lip 2024 · Pathological type and treatment options of atrial septal defects (ASDs). Types of ASDs include ostium secundum (A), ostium primum (B), sinus venosus (C), and coronary sinus (D) defects. Treatment strategies are based on ASD type and morphology.
18 lut 2023 · Diagnosis of FHF is based on various fetal echocardiographic findings, depending on the severity of cardiac dysfunction, including cardiomegaly, poor contractility, low cardiac output, venous congestion, effusions, and typical findings of specific cardiac anomalies.
15 gru 2017 · The objective of this systematic review and meta‐analysis was to compare the efficacy, safety, and fetal–maternal tolerance of first‐line monotherapies for fetal SVT and AF to provide comparative effectiveness inferences about the preferred first‐line therapy.
